Clinical trials
Recurrent Implantation Failure clinical trials
Below are recruiting recurrent implantation failure clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06762626Recruiting
Comparing two methods of timing a frozen embryo transfer
This trial compares a new method to time a frozen embryo transfer (using a test called ERA) with the standard method. The goal is to find the best time to transfer a high-quality embryo in women who have had multiple failed IVF attempts (recurrent implantation failure).
Hong KongAges 18–40 - NCT03900780Recruiting
Genetic testing of embryos for repeat IVF failure
This study tests embryos before pregnancy using genetic screening to look for extra or missing chromosomes, in people who have had repeated IVF embryo transfers without success. It may help reduce the chance of transferring embryos that are unlikely to result in a healthy pregnancy.
LeuvenAges 18–40 - NCT07669623Recruiting
Acupuncture for recurrent implantation failure
This trial tests whether different acupuncture techniques can improve pregnancy success in people who have had repeated failed embryo transfers. It may help you if you are planning a frozen embryo transfer.
Wuhan, HubeiAges 20–40 - NCT05930613RecruitingPhase 3
Certolizumab for repeated embryo transfer pregnancy failure
This Phase 3 study tests certolizumab to help people with repeated embryo transfer failures achieve a clinical pregnancy. It may be an option if your infertility has no known cause and you meet the other study checks.
ParisAges 18–40 - NCT07675980RecruitingPhase 2/Phase 3
Thymosin-α1 for repeated IVF failure
This trial tests whether a drug called thymosin-α1 can help women who have had two or more failed embryo transfers with genetically normal embryos. It aims to improve the chances of successful implantation.
Abu DhabiAges 18–40 - NCT05169541Recruiting
Testing a blood marker in repeated pregnancy loss
This study looks at whether a blood protein level called mannose binding lectin is linked to why some people have repeated pregnancy loss or unsuccessful embryo transfers. If you’ve had multiple losses or failed transfers, the study may help clarify biology behind reproduction and could guide future care.
AarhusAges 18–41 - NCT05648136Recruiting
Blood test study for immune markers in miscarriage and IVF failure
This study looks at immune-related blood patterns and other measurements to better understand why some women have repeated pregnancy loss or repeated IVF implantation failure. If you qualify, your answers and test results may help researchers identify biomarkers that could guide future care.
Amiens, PicardieAges 18–39 - NCT05343572RecruitingEarly Phase 1
Stem cell treatment to improve abnormal uterine lining
This early-phase study tests whether mobilized stem cells from bone marrow can help women with certain abnormal uterine lining problems become healthier and possibly improve fertility. It’s aimed at people who are not pregnant and meet specific diagnoses and test results.
Orange, ConnecticutAges 18–40 - NCT06847386Enrolling by invitation
Uterine surgery for women with repeated IVF failure
This trial tests whether a surgical procedure to reshape the uterus can improve the chances of a successful embryo transfer in women who have had at least two failed IVF attempts.
Shanghai, Shanghai MunicipalityAges 20–40 - NCT06645379Recruiting
Platelet-rich plasma for fertility treatments
This trial tests whether injecting platelet-rich plasma (a concentrate from your own blood) into the uterus or ovaries can help women with certain fertility issues, such as damaged uterine lining, scarring, or low egg reserve. It aims to improve pregnancy chances in these challenging cases.
Yiwu, ZhejiangAges 18–50 - NCT07632586Recruiting
First-in-Human Heart Pump Implant Study
This trial tests a new tiny heart pump called the Icoms Flowmaker for patients with severe heart failure who cannot have a standard heart pump. The device may help your heart pump blood better and improve your ability to do daily activities.
PragueAges 18–80 - NCT04671771Recruiting
Testing a new graft for hemodialysis access in kidney failure
This study tests whether an “AV graft” implant works safely and well for people with end-stage kidney disease who need hemodialysis. It may help your dialysis access last and work better, compared with current expectations for AV grafts.
Phoenix, ArizonaAges 18–90 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age
Hear when a new Recurrent Implantation Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent implantation failure?
- Yes. Clin2 currently lists 13 recruiting recurrent implantation failure studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent implantation failure trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent implantation failure trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.